Stock Events

Stock Events

Lite Strategy 

$1.15
43
+$0.01+0.44% Today

Statistics

Day High
1.19
Day Low
1.14
52W High
9
52W Low
0.95
Volume
98,943
Avg. Volume
-
Mkt Cap
41.63M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 23
$1.75
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.39
-0.06
0.28
0.61
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-31.89MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LITS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
TG Therapeutics
TGTX
Mkt Cap5.4B
TG Therapeutics focuses on novel treatments for B-cell malignancies and autoimmune diseases, directly competing with MEI Pharma's cancer therapy developments.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation specializes in oncology products, including therapies for hematologic cancers, overlapping with MEI Pharma's research and development focus.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a major player in the development of treatments for cancer and other diseases, competing with MEI Pharma in the oncology sector.
Agios Pharmaceuticals
AGIO
Mkt Cap1.67B
Agios Pharmaceuticals focuses on cellular metabolism to develop therapies for cancer, directly competing with MEI Pharma's approach to cancer treatment.
Karyopharm Therapeutics
KPTI
Mkt Cap209.65M
Karyopharm Therapeutics focuses on nuclear export inhibitors for cancer treatment, competing in the same therapeutic area as MEI Pharma.
Novartis
NVS
Mkt Cap279.67B
Novartis is a large pharmaceutical company with a broad oncology portfolio, making it a competitor across various aspects of MEI Pharma's business.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb has a diverse range of cancer treatments, including therapies that directly compete with MEI Pharma's product pipeline.

About

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Show more...
CEO
Mr. Justin J. File CPA
Employees
4
Country
United States
ISIN
US55279B3015

Listings

XNAS
US
LITS
STU
DE
MMI0.STU
LSE
GB
0JW9.LSE
BOATS
BOATS
LITS.BOATS

0 Comments

Share your thoughts

FAQ

What is Lite Strategy stock price today?▼
The current price of LITS is $1.15 USD — it has increased by +0.44% in the past 24 hours. Watch Lite Strategy stock price performance more closely on the chart.
What is Lite Strategy stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lite Strategy stocks are traded under the ticker LITS.
What is Lite Strategy market cap?▼
Today Lite Strategy has the market capitalization of 41.63M
When is the next Lite Strategy earnings date?▼
Lite Strategy is going to release the next earnings report on May 07, 2026.
What is Lite Strategy revenue for the last year?▼
Lite Strategy revenue for the last year amounts to 0 USD.
What is Lite Strategy net income for the last year?▼
LITS net income for the last year is -31.89M USD.
Does Lite Strategy pay dividends?▼
Yes, LITS dividends are paid en. The last dividend per share was 1.75 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Lite Strategy have?▼
As of May 06, 2026, the company has 4 employees.
In which sector is Lite Strategy located?▼
Lite Strategy operates in the Health & Wellness sector.
When did Lite Strategy complete a stock split?▼
The last stock split for Lite Strategy was on April 17, 2023 with a ratio of 1:20.
Where is Lite Strategy headquartered?▼
Lite Strategy is headquartered in San Diego, United States.